Rachel B. Wagman

No ORCID on file · 13 papers in corpus · active 2020-2024

Study types

  • article 13

Condition tags

  • endometriosis 11
  • dysmenorrhea 5
  • mesh:D004715 3
  • mesh:D017699 3
  • mesh:D004412 2
  • dyspareunia 2
  • mesh:D004414 1
article 2024
P-308 Relugolix combination therapy vs relugolix monotherapy with transition to relugolix combination therapy for the treatment of endometriosis-associated pain: implications for cumulative benefit/risk profile
·doi:10.1093/humrep/deae108.273

Abstract Study question How does the benefit/risk profile compare in women with endometriosis-associated pain who initiated relugolix combination therapy (Relugolix-CT) vs relugolix monotherapy with transition to Relugolix-CT? Summary answe…

article 2024
Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study
Human Reproduction ·doi:10.1093/humrep/dead263

STUDY QUESTION: What is the efficacy and safety of long-term treatment (up to 2 years) with relugolix combination therapy (CT) in women with moderate to severe endometriosis-associated pain? SUMMARY ANSWER: For up to 2 years, treatment with…

article 2023
A Plain Language Summary to Learn About Relugolix Combination Therapy for the Treatment of Pain Associated with Endometriosis
Pain management ·doi:10.2217/pmt-2023-0052

WHAT IS THIS SUMMARY ABOUT?: This is a summary of research studies (known as clinical trials) called SPIRIT 1 and SPIRIT 2. The SPIRIT 1 and SPIRIT 2 studies compared how well a medicine called relugolix combination therapy worked in reliev…

article 2023
BONE MINERAL DENSITY AFTER TWO YEARS OF TREATMENT WITH RELUGOLIX COMBINATION THERAPY AND ONE-YEAR POST-TREATMENT FOLLOW-UP IN WOMEN WITH ENDOMETRIOSIS: SPIRIT PROGRAM
·doi:10.1016/j.fertnstert.2023.08.234
article 2022
EVALUATION OF THE EFFECT OF RELUGOLIX COMBINATION THERAPY ON BONE MINERAL DENSITY (BMD) OVER TWO YEARS IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: SPIRIT LONG-TERM EXTENSION (LTE) STUDY
·doi:10.1016/j.fertnstert.2022.08.631
article 2022
O-305 SPIRIT long-term extension study: two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain
·doi:10.1093/humrep/deac105.102

Abstract Study question To assess the long-term efficacy and safety of once-daily Relugolix combination therapy (Relugolix-CT) in the treatment of endometriosis-associated pain over two years. Summary answer Relugolix-CT previously demonstr…

article 2022
Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2)
Lancet (London, England) ·doi:10.1016/s0140-6736(22)00622-5

BACKGROUND: Endometriosis is a common cause of pelvic pain in women, for which current treatment options are suboptimal. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, combined with estradiol and a progestin, was eva…

article 2022
TIME TO MINIMAL OR NO PELVIC PAIN WITH RELUGOLIX COMBINATION THERAPY IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: RESULTS FROM THE SPIRIT PROGRAM
·doi:10.1016/j.fertnstert.2022.08.035
article 2021
ASSESSMENT OF COMMON ADVERSE EVENTS OF RELUGOLIX COMBINATION THERAPY IN PREMENOPAUSAL WOMEN TREATED FOR SYMPTOMATIC ESTROGEN-DRIVEN CONDITIONS: LIBERTY AND SPIRIT STUDIES
·doi:10.1016/j.fertnstert.2021.07.038
article 2021
INTEGRATED LONG-TERM BONE MINERAL DENSITY (BMD) OUTCOMES IN WOMEN RECEIVING RELUGOLIX COMBINATION THERAPY IN LIBERTY AND SPIRIT STUDIES VS NON-TREATED WOMEN
·doi:10.1016/j.fertnstert.2021.07.144
article 2021
O-132 Sustained efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT 52-week data
·doi:10.1093/humrep/deab126.057

Abstract Study question To assess the long-term (52-week) efficacy and safety of relugolix combination therapy (Relugolix-CT) in the treatment of endometriosis-associated pain. Summary answer Relugolix-CT demonstrated a sustained improvemen…

article 2021
Sustained Efficacy and Safety of Relugolix Combination Therapy in Women with Endometriosis-Associated Pain: Spirit 52-Week Data
·doi:10.1016/j.jmig.2021.09.031
article 2020
EFFICACY AND SAFETY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (SPIRIT 2)
·doi:10.1016/j.fertnstert.2020.08.238